U-NEURON BIOMEDICAL held its investor conference on the 22nd, unveiling three key highlights of its future operations: its allogeneic stem cell drug candidate UA002 is set to enter Phase II clinical trials; its "deer amniotic fluid" product line will be distributed through nearly 5,000 Créscendia (克麗緹娜) locations across China and Taiwan starting in the second half of the year; and it is expanding its deer antler-derived exosome product applications, particularly in dental treatments, with plans to enter the Malaysian market.
As one of the few biotech companies globally—and a pioneering one in Taiwan—U-NEURON BIOMEDICAL holds patented technology for the isolation and cultivation of amniotic fluid stem cells, invented by Dr. Huang, Shiaw-min, the “father of amniotic fluid stem cells.” During the conference, Chairman Jian Feng-Ren and the executive team outlined the company's 2025 R&D roadmap and expansion strategy for its stem cell product pipeline.
Jian highlighted the 2023 U.S. FDA approval of the first allogeneic stem cell product, Ryoncil, as a major market motivator. U-NEURON’s UA002, targeting oral drug-resistant erectile dysfunction (ED), has passed safety evaluations and is poised to enter Phase II clinical trials. The company has attracted several international experts in male sexual medicine who are interested in UA002 and plan to collaborate on clinical trials and licensing talks, aiming to capture a share of the USD 6.74 billion global ED market.
Meanwhile, the growing popularity of exosomes has propelled U-NEURON to the forefront of innovation. The company was the first in the world to obtain INCI certification for exosomes derived from fawn amniotic fluid stem cells. It now holds five INCI registrations, including those for exosomes derived from fawn amniotic fluid and deer antler stem cells—more than any other company. Its amniotic fluid stem cell exosome skincare products, in partnership with Créscendia, were officially launched in Taiwan in January 2024. A grand product launch will follow in Wuhan on May 9. Sales through nearly 5,000 stores in China and Taiwan are expected to begin contributing revenue in the second half of the year, with the rapid expansion of distribution points expected to drive substantial growth.
In terms of new application areas, Dr. Huang, in addition to developing the original fawn amniotic fluid exosome ingredient, has also pioneered deer antler-derived exosome raw materials through patented extraction technology—another major innovation for the company. U-NEURON is collaborating with GLAC BIOTECH to explore the potential of deer antler-derived exosomes in hair regeneration and dental bone grafting. GLAC BIOTECH founder Shang-Ming Wang was invited to the conference to present the impressive research outcomes of this joint effort.
Wang explained that deer antler-derived exosomes are rich in active compounds and show potential for promoting hair follicle growth and improving the follicular microenvironment. Preliminary research revealed that in alveolar bone reconstruction, these exosomes outperform conventional treatments. In collaboration with clinicians in Southeast Asia, bone grafting techniques using deer antler-derived exosomes have shown promising results in dental implant repairs by accelerating and enhancing osseointegration, significantly reducing surgery time and risk. Trials have also confirmed the exosomes’ ability to promote hair regeneration in common male and female hair loss conditions. However, Wang emphasized that further research is necessary before these applications can become mainstream clinical treatments.
To capitalize on the rapidly growing Southeast Asian and halal markets, U-NEURON has established a cell culture lab at the Sarawak Biodiversity Centre in Malaysia and will apply for halal certification locally. From Malaysia, the company plans to expand into other Southeast Asian countries and eventually enter the affluent Muslim markets of the Arab world. Starting in the second half of this year, GLAC BIOTECH will work with U-NEURON to launch deer antler exosome products in Malaysia, opening a gateway to Southeast Asia’s fast-growing market and laying the foundation for Muslim market entry.
Jian concluded by stating that the next five years will mark an explosive growth phase for U-NEURON. Beyond significant revenue gains, the company will continue to innovate in both biomedicine and nutraceuticals. Its partnerships, distribution networks, and international reach will keep expanding. By leveraging its platforms in amniotic fluid stem cells and deer antler-derived exosome technologies, U-NEURON aims to deepen its patent moat, solidify its intellectual property value, and deliver strong investment returns for shareholders.
Resource: 永立榮法說會: 拓展鹿茸外泌體至牙科應用 進軍東南亞市場
